Hereditary Angioedema Pipeline Shows Robust Growth with 30+ Therapies in Development Across Multiple Clinical Stages
核心洞察
DelveInsight's 2025 pipeline report reveals over 20 companies are actively developing more than 30 therapeutic candidates for hereditary angioedema (搜索) treatment across various clinical stages.
Recent clinical developments include CSL Behring's Phase 3b study of garadacimab (CSL312) announced in August 2025 and KalVista's pediatric trial of KVD900 for patients aged 2-11 years.
Leading pipeline therapies span multiple approaches including oral plasma kallikrein (搜索) inhibitors, gene therapies, and monoclonal antibodies, with products in late-stage development showing promise for addressing unmet medical needs.
The hereditary angioedema (搜索) (HAE) therapeutic landscape is experiencing significant expansion, with DelveInsight's comprehensive 2025 pipeline report identifying more than 20 active companies developing over 30 pipeline therapies for this rare genetic disorder. The robust pipeline spans multiple clinical development stages and represents diverse therapeutic approaches to address the substantial unmet medical needs in HAE treatment.
Recent Clinical Developments Drive Pipeline Momentum
Several key clinical milestones have marked recent progress in the HAE pipeline. On August 19, 2025, CSL Behring announced the initiation of a Phase 3b study to evaluate the long-term safety and efficacy of CSL312 (garadacimab) when administered subcutaneously. This development represents a significant advancement for the company's HAE program.
KalVista Pharmaceuticals has also made notable progress, announcing on September 17, 2025, the launch of study KVD900-303, an open-label, multicenter clinical trial targeting pediatric patients aged 2 to 11 years with HAE Type I or II. Additionally, BioCryst Pharmaceuticals conducted a Phase 3b open-label study on September 19, 2025, providing expanded access to berotralstat for HAE patients previously enrolled in berotralstat studies through the APeX-A, 7353-312 single-arm, multicenter study.
Leading Pipeline Candidates Show Diverse Therapeutic Approaches
Late-Stage Development Programs
KVD900 from KalVista Pharmaceuticals represents one of the most advanced oral treatment options in development. This plasma kallikrein (搜索) inhibitor exhibits high solubility and high permeability, making it uniquely suited for on-demand treatment of HAE attacks with rapid plasma uptake and high plasma concentrations. The drug is currently in Phase III development for hereditary angioedema (搜索) treatment.
Mid-Stage Innovations
PHA121 from Pharvaris is advancing as a novel small molecule with drug-like properties currently in Phase II development. In preclinical studies, PHA121 demonstrated highly potent and selective competitive antagonism of the B2 receptor (搜索), showing rapid and potent activity on oral dosing in bradykinin-mediated disease models.
Early-Stage Gene Therapy Approaches
BMN 331 from BioMarin Pharmaceutical represents the gene therapy approach to HAE treatment and is currently in Phase I stage of development, potentially offering a transformative treatment paradigm for patients with this genetic disorder.
Comprehensive Therapeutic Landscape
The pipeline encompasses a broad range of promising therapies including NTLA-2002, Donidalorsen, STAR-0215, Garadacimab, TAK-743 300 mg, ADX-324, CSL312, TAK-667, and Lanadelumab. These candidates represent various molecular approaches including gene therapies, small molecules, peptides, and monoclonal antibodies.
Leading companies driving innovation in this space include Corcept Therapeutics, BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals (搜索), and Intellia Therapeutics, among others.
Multiple Routes of Administration Expand Treatment Options
The diverse pipeline offers multiple administration routes to meet different patient needs, including infusion, intradermal, intramuscular, intranasal, intravenous, oral, parenteral, subcutaneous, and topical delivery methods. This variety of delivery mechanisms could significantly improve patient compliance and treatment outcomes.
Disease Background Drives Innovation
Hereditary angioedema (搜索) is characterized by recurrent episodes of severe swelling affecting the limbs, face, intestinal tract, and airway. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting, while minor trauma or stress may trigger attacks, though swelling often occurs without known triggers. This unpredictable nature of the disease underscores the critical need for effective therapeutic interventions.
The robust pipeline development activity reflects the significant unmet medical needs in HAE treatment and the potential for multiple therapeutic approaches to address different aspects of disease management, from acute attack treatment to long-term prophylaxis.